Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

Harrow will announce Q4 2025 financial results on March 2, 2026, followed by a conference call on March 3, 2026.

Quiver AI Summary

Harrow, a prominent provider of ophthalmic disease management solutions in North America, announced that it will release its financial results for the fourth quarter and year ending December 31, 2025, on March 2, 2026, after market close. The company will also share its fourth quarter Letter to Stockholders on its website. A conference call and live webcast are scheduled for March 3, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Interested participants can access the webcast on Harrow's website or register in advance for telephone participation. Harrow focuses on delivering safe, effective, and accessible medications for various ocular conditions to improve patient outcomes.

Potential Positives

Harrow is set to release its financial results for the fourth quarter and full year of 2025, which may provide insights into the company's growth and performance.
A live conference call and webcast will be held to discuss the results, promoting transparency and engagement with investors.
Harrow's commitment to delivering safe and effective ophthalmic solutions reinforces its positioning as a leader in the industry.

Potential Negatives

The press release does not provide any financial information or performance metrics, which could lead to uncertainty among investors regarding the company's current financial health.
The timing of the financial results announcement after market close could imply that the results may not be favorable, as companies often release good news during market hours to capitalize on the positive sentiment.
Harrow's future business updates are contingent upon the upcoming results, creating potential volatility in stock prices depending on the outcome of the earnings report.

FAQ

When will Harrow announce its fourth-quarter earnings?

Harrow will report its financial results on March 2, 2026, after market close.

How can I access the Harrow conference call?

Participants can access the call via the live webcast on Harrow's "Investors" page or by telephone after registration.

What time is the Harrow conference call scheduled?

The conference call is scheduled for 8:00 a.m. Eastern Time on March 3, 2026.

Where can I find Harrow's fourth quarter Letter to Stockholders?

The Letter to Stockholders will be posted in the "Investors" section of Harrow's website, harrow.com.

What services does Harrow provide?

Harrow specializes in ophthalmic disease management solutions, offering treatments for various eye conditions.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$HROW Insider Trading Activity

$HROW insiders have traded $HROW stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $HROW stock by insiders over the last 6 months:

MANAGEMENT INC. OPALEYE sold 20,000 shares for an estimated $1,066,914

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$HROW Revenue

$HROW had revenues of $71.6M in Q3 2025. This is an increase of 45.44% from the same period in the prior year.

You can track HROW financials on Quiver Quantitative's HROW stock page.

$HROW Hedge Fund Activity

We have seen 103 institutional investors add shares of $HROW stock to their portfolio, and 109 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

LUXOR CAPITAL GROUP, LP added 610,204 shares (+198.5%) to their portfolio in Q4 2025, for an estimated $29,899,996
CITADEL ADVISORS LLC removed 392,086 shares (-58.6%) from their portfolio in Q3 2025, for an estimated $18,890,703
MARSHALL WACE, LLP removed 307,809 shares (-60.6%) from their portfolio in Q4 2025, for an estimated $15,082,641
D. E. SHAW & CO., INC. removed 202,686 shares (-97.4%) from their portfolio in Q3 2025, for an estimated $9,765,411
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 199,526 shares (-44.4%) from their portfolio in Q4 2025, for an estimated $9,776,774
IKARIAN CAPITAL, LLC added 183,347 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,984,003
FIRST TURN MANAGEMENT, LLC removed 160,234 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,851,466

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$HROW Analyst Ratings

Wall Street analysts have issued reports on $HROW in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Ladenburg Thalmann issued a "Buy" rating on 11/12/2025
HC Wainwright & Co. issued a "Buy" rating on 11/12/2025
B. Riley Securities issued a "Buy" rating on 10/01/2025
BTIG issued a "Buy" rating on 09/29/2025
Lake Street issued a "Buy" rating on 09/29/2025

To track analyst ratings and price targets for $HROW, check out Quiver Quantitative's $HROW forecast page.

$HROW Price Targets

Multiple analysts have issued price targets for $HROW recently. We have seen 6 analysts offer price targets for $HROW in the last 6 months, with a median target of $67.5.

Here are some recent targets:

Yi Chen from HC Wainwright & Co. set a target price of $69.0 on 11/12/2025
Jeffrey Cohen from Ladenburg Thalmann set a target price of $66.0 on 11/12/2025
Mayank Mamtani from B. Riley Securities set a target price of $74.0 on 10/01/2025
Thomas Flaten from Lake Street set a target price of $70.0 on 09/29/2025
Thomas Shrader from BTIG set a target price of $63.0 on 09/29/2025
Chase Knickerbocker from Craig-Hallum set a target price of $64.0 on 09/23/2025

Full Release

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com . Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update.

Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn .

Contact:
Mike Biega
VP of Investor Relations & Communications
[email protected]
617-913-8890